Amylyx Pharmaceuticals hopes to launch largest PSP trial to date

The treatment of rare brain disease, progressive supranuclear palsy (PSP), that has no disease modifying therapies, has been given a glimmer of hope by Amylyx Pharmaceuticals.

Related Keywords

United States ,Japan ,Germany ,Munich ,Bayern ,America ,Lahar Mehta ,International Research Symposium ,Movement Disorder Society ,Department Of Neurology At ,North America ,Progressive Supranuclear Palsy Rating Scale ,Movement Disorder Society Unified Parkinson ,Disease Rating Scale Part ,Clinical Development ,Preclinical Research ,Pis Active Pharmaceutical Ingredients ,Hasei Ii ,Phase Iii Iv ,Progressive Supranuclear Palsy ,Clinical Trials ,Data Management ,Atient Centricity ,Patient Recruitment ,Neurodegenerative Diseases ,Rare Disease ,